Berry Genomics, Prenetics create JV to deliver consumer digital health, genetics testing services in mainland China

Berry Genomics and consumer digital health and genetics testing company Prenetics will establish a joint venture (JV) to deliver consumer digital health and genetics testing services in mainland China, the companies announced Thursday. Financial terms of the JV, which the companies said is the first of its kind to operate in China, were not disclosed.

Daixing Zhou, Berry Genomics CEO, remarked "we are extremely excited about the potential of the direct-to-consumer testing market in mainland China…By joining forces with Prenetics, we believe that we can effectively complement one another and ultimately provide valuable benefits to millions of people across mainland China." Meanwhile, Danny Yeung, CEO of Prenetics, noted that Berry Genomics is an "industry leader" in noninvasive prenatal tests and "has developed a proven business model in genomics around a complex challenge in mainland China." Yeung added that "everyone should have access to high-quality and affordable genetic testing and digital health services. Together with Berry, we will create awareness on health and the power of prevention through genetic understanding."

According to Berry Genomics and Prenetics, the JV will provide a range of integrated digital health and genetics testing services aimed at helping consumers understand their genes and how they relate to their health. The companies said they will work on a direct-to-consumer model that allows consumers to purchase a suite of genetics enabled health services directly online. The services are expected to be launched in the first quarter of 2019.

Did you like this article?